Patients with multiple sclerosis (MS) who also have food allergies have more relapses than patients with no known food allergy, according to a new study published in the Journal of Neurology, Neurosurgery & Psychiatry.
Patients with multiple sclerosis (MS) who also have food allergies have more relapses than patients with no known food allergy, according to a new study published in the Journal of Neurology, Neurosurgery & Psychiatry.
A set of 1349 patients completed a self-administered questionnaire on environmental, food, and drug allergies, and they were distributed among 4 allergy groups: environmental (n = 586), food (n = 238), drug (n = 574), and no known allergies (NKA; n = 427).
The researchers then assessed clinical variables—the number of attacks, expanded disability status scale (EDSS), and MS severity score (MSSS)—and radiological variables—presence of gadolinium-enhancing lesions and lesion count—and the association of these variables with the different allergy groups.
"Our findings suggest that MS patients with allergies have more active disease than those without, and that this effect is driven by food allergies," wrote the researchers.
Compared with the NKA group, patients with food allergies had a 1.38 times higher rate for cumulative number of attacks (P = .0062). The food allergy group also showed more than twice the likelihood (P = .0096) of having gadolinium-enhancing lesions on magnetic resonance imaging than the NKA group.
The initial analysis indicated that any allergy was associated with a 22% higher rate of cumulative disease bouts compared with NKA, but that difference disappeared after taking into account potentially influential factors.
“Future prospective studies are needed to confirm our findings and investigate underlying biological mechanisms, which may unveil new therapeutic and preventative strategies for MS,” the authors concluded.
Reference
Fakih R, Diaz-Cruz C, Chua AS, et al. Food allergies are associated with increased disease activity in multiple sclerosis [published online December 18, 2018]. J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2018-319301.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More